Clinical analysis of vinorereabine combined with bevacizumab in non-small cell cancer patients

doi:10.3877/cma.j.issn.1674-6902.2021.06.008

Abstract

Abstract:

Objective

To analyze the clinical efficacy and survival of vinorereabine combined with bevacizumab for non-small cell lung cancer (NSCLC).

Methods

42 cases with NSCLC treated by our hospital from April 2017 to March 2020 were collected for this study. According to the clinical treatment, all of the cases were divided into observation group (22 cases) and control group (20 cases). In control group, patient with cisplatin plus vinorereabine. In observation group, patients treated combined with bevacizumab on a control basis. The clinical efficacy of two groups was evaluated after 2 weeks of treatment, serum tumor factors [serum angiopoietin-like protein 2 (ANGPTL2), antimicrobial peptide human cationic antimicrobial protein 18 (hCAP18) and serum carcincoembryonic antigen (CEA)] levels, adverse drug effects, and survival after 12-month follow-up.

Results

In observation group, the disease control rate was higher than control group (P<0.05). After treatment, the serum hCAP18, CEA and ANGPTL2 levels were lower than before, and the observation group was lower than control group(P<0.05). The 1-year survival rate, observation group was higher than control group (P<0.05). There was no significant difference in the incidence of adverse reactions in two groups(P>0.05).

Conclusion

Vinorereabine combined with bevacizumab in NSCLC patients, to improve the clinical efficacy of patients, improve the disease control rate of patients, reduce the serum levels of hCAP18, CEA and ANGPTL2 in patients, improve the 1-year survival rate of patients, and better safety.

Key words: Bevacizumab, Non-small cell cancer, Clinical efficacy

Wangtianyi Shi, Jing Wu, Chenting Miao. Clinical analysis of vinorereabine combined with bevacizumab in non-small cell cancer patients[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2021, 14(06): 745-748.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2021.06.008

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2021/V14/I06/745

Figures/Tables 1

References 30

1	李慧婷，莫冉冉，宋　鹏，等. 非小细胞肺癌免疫检查点抑制剂治疗进展[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 382-386.
2	陈宏达，郑荣寿，王　乐，等. 2019年中国肿瘤流行病学研究进展[J]. 中华疾病控制杂志，2020, 24(4): 373-379.
3	邓小茜，戈　伟. SBRT与IMRT治疗早期非小细胞肺癌的疗效与生存情况分析[J]. 武汉大学学报(医学版), 2020, 41(5): 754-757.
4	Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24): 2288-2301.
5	韩文杰，刘　军，孙永臣. 红参发酵产物联合长春瑞滨及顺铂化疗方案治疗晚期非小细胞肺癌患者的疗效[J]. 癌症进展，2020, 18(7): 694-698.
6	Proto C, Ferrara R, Signorelli D, et al. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out[J]. Cancer Treat Rev, 2019, 75(3): 39-51.
7	Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial [J]. Lancet Oncol, 2019, 20(5): 625-635.
8	黄　彬. 贝伐单抗和顺铂联合治疗非小细胞肺癌恶性胸腔积液的疗效评价[J]. 国际呼吸杂志，2016, 36(11): 814-817.
9	Manzo A, Montanino A, Carillio G, et al. Angiogenesis Inhibitors in NSCLC[J]. Int J Mol Sci, 2017, 18(10): 114-116.
10	支修益，石远凯，于金明. 中国原发性肺癌诊疗规范(2015年版)[J]. 中华肿瘤杂志，2015, 37(1): 67-78.
11	Reck M, Mok T, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial[J]. Lancet Respir Med, 2019, 7(5): 387-401.
12	Assoun S, Brosseau S, Steinmetz C, et al. Bevacizumab in advanced lung cancer: state of the art[J]. Future Oncol, 2017, 13(28): 2515-2535.
13	Russo AE, Priolo D, Antonelli G, et al. Bevacizumab in the treatment of NSCLC: patient selection and perspectives[J]. Lung Cancer (Auckl), 2017, 8(10): 259-269.
14	Alshangiti A, Chandhoke G, Ellis PM. Antiangiogenic therapies in non-small-cell lung cancer[J]. Curr Oncol, 2018, 25(7): S45-S58.
15	Masuda C, Yanagisawa M, Yorozu K, et al. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model [J]. Int J Oncol, 2017, 51(2): 425-434.
16	Ramalingam SS, Dahlberg SE, Belani CP, et al. Pemetrexed, bevacizumab，or the combination as maintenance therapy for advanced nonsquamous non-small-cell lung cancer: ECOG-ACRIN 5508[J]. J Clin Oncol, 2019, 37(26): 2360-2367.
17	李　航，王　莹，张春江，等. 肿瘤坏死因子相关诱导凋亡配体联合长春瑞滨联合干预诱导肺癌A549细胞凋亡及其机制[J]. 中华实验外科杂志，2016, 33(1): 112-114.
18	宋小珍，贾亚辉，张跃强. 长春瑞滨联合阿帕替尼治疗中晚期非小细胞肺癌的临床疗效及预后观察[J]. 实用癌症杂志，2020, 35(12): 1997-2000.
19	Herbst RS, Redman MW, Kim ES, et al. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study[J]. Lancet Oncol, 2018, 19(1): 101-114.
20	Dhillon S, Syed YY. Atezolizumab first-line combination therapy: a review in metastatic nonsquamous NSCLC[J]. Target Oncol, 2019, 14(6): 759-768.
21	薛　琴，传锋彬，唐　甦. CT引导下¹²⁵I粒子植入联合贝伐单抗对非小细胞肺癌的疗效[J]. 实用癌症杂志，2020, 35(3): 418-420.
22	Manegold C, Dingemans AC, Gray JE, et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC[J]. J Thorac Oncol, 2017, 12(2): 194-207.
23	Reck M, Wehler T, Orlandi F, et al. Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non-small-cell lung cancer[J]. J Clin Oncol, 2020, 38(22): 2530-2542.
24	Jiang T, Zhang Y, Li X, et al. EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases[J]. Eur J Cancer, 2019, 121(7): 98-108.
25	Wakelee HA, Dahlberg SE, Keller SM, et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1610-1623.
26	Reinmuth N, Bryl M, Bondarenko I, et al. PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin((R))), both plus paclitaxel and carboplatin, as first-line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study[J]. BioDrugs, 2019, 33(5): 555-570.
27	Reck M, Shankar G, Lee A, et al. Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations[J]. Expert Rev Respir Med, 2020, 14(2): 125-136.
28	Thatcher N, Goldschmidt JH, Thomas M, et al. Efficacy and Safety of the Biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (MAPLE): A randomized, double-blind, phase Ⅲ study[J]. Clin Cancer Res, 2019, 25(7): 2088-2095.
29	Gridelli C, de Castro CJ, Dingemans AC, et al. Safety and efficacy of bevacizumab plus standard-of-care treatment beyond disease progression in patients with advanced non-small cell lung cancer: The AvaALL randomized clinical trial[J]. JAMA Oncol, 2018, 4(12): e183-e186.
30	Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial[J]. JAMA Oncol, 2018, 4(1): e173-e175.

组　别	例数	hCAP18(μg/L)		CEA(μg/ml)		ANGPTL2(pg/ml)
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	22	6 572.13±684.12	3 217.08±312.84^a	80.48±6.42	13.56±3.31^a	6 359.11±1 784.02	4 189.76±1 472.61^a
对照组	20	6 581.44±973.52	4 997.05±487.29^a	80.22±6.13	20.56±5.21^a	6 415.46±1 791.33	5 219.17±1 743.25^a
t组		0.036	14.219	0.134	5.247	0.102	2.074
P值		0.971	<0.001	0.894	<0.001	0.919	0.045

组　别	例数	hCAP18(μg/L)		CEA(μg/ml)		ANGPTL2(pg/ml)
组　别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	22	6 572.13±684.12	3 217.08±312.84^a	80.48±6.42	13.56±3.31^a	6 359.11±1 784.02	4 189.76±1 472.61^a
对照组	20	6 581.44±973.52	4 997.05±487.29^a	80.22±6.13	20.56±5.21^a	6 415.46±1 791.33	5 219.17±1 743.25^a
t组		0.036	14.219	0.134	5.247	0.102	2.074
P值		0.971	<0.001	0.894	<0.001	0.919	0.045

[1]	Hua Zhang, Yu Sun, Shijian Xiang, Yingmei Li, Xiaoqun Wang. Research on chemosensitivity evaluation using circulating tumor cells in advanced gastrointestinal cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 422-425.
[2]	Yi Dong, Meng Yang, Zheng Wang, Ai'min Jiang, Zongqin Zhang, Zhenjie Wu, Linhui Wang, hong Xu, Bing Liu. Clinical experiences and efficacy of plasmakinetic anatomical enucleation of the prostate with cylindrical electrode [J]. Chinese Journal of Endourology(Electronic Edition), 2022, 16(05): 413-418.
[3]	Yongli Cao, Siyuan Wang, Yilu Li, Bingbing Lv, Chunxu Zhang, Yang Yang, Yuanyao Zhang, Weiwei Yang, Wenli Zhang, Dong Wei. Clinical observation of laparoscopic subtotal colostomy and ceco-rectal anastomosis in the treatment of senile slow transit constipation [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(05): 392-398.
[4]	Yao Huang, Bin Yuan, Hao Shu, Lei Wang, Luning Sun. Clinical observation of the treatment of type V SLAP injury with anchor repairment under arthroscope [J]. Chinese Journal of Shoulder and Elbow(Electronic Edition), 2023, 11(03): 218-223.
[5]	Linyuan Zhang, Jiajun Wu, Xu Cui, Chao Shen, Beigang Fu, Yin Cui, Xiuhui Wang, Pan Cai. Efficacy difference between APGT and PHILOS fixation for Mutch I/II greater tuberosity fractures with shoulder dislocations [J]. Chinese Journal of Shoulder and Elbow(Electronic Edition), 2023, 11(02): 139-145.
[6]	Wenlong Liang, Jie Cao, Qing Huang, Yong Lin, Hongli Huang, Ping Yang, Guanwei Li, He Hu. Efficacy and safety analysis of sintilimab combined with regofenib in the treatment of advanced colorectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 409-413.
[7]	Lijiao Jiang, Feng Zhang, Yuping Zhou. Clinical efficacy observation of treating elderly patients with acute non-variceal upper gastrointestinal hemorrhage using the MDT model [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 520-524.
[8]	Jing Sheng, Yong Mei, Pei Xia, Xiaolin Wang. Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 317-321.
[9]	Jingxu Zhang, Defang Li, Shangke You, Yutian Zhang. Clinical efficacy of bevacizumab and anlotinib combined with oxaliplatin in the treatment of advanced rectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(05): 289-293.
[10]	Xiaodong Yu, Dehua Li, Shan Gao, Xin Xu. Clinical observation on the treatment of mild active Crohn′s disease by combining Jiawei Lizhong Decoction with mesalazine [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 199-202.
[11]	Jun Zhao, Chaojie Li, Jia Li. Curative effect of rabeprazole combined with Kangfuxin solution on duodenal ulcer with positive Helicobacter pylori infection [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 254-258.
[12]	Jun Dong, Fangfang Wu. Clinical efficacy and safety analysis of mFOLFOX6 and FOLFOX4 chemotherapy regimens in the treatment of rectal cancer [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(04): 236-240.
[13]	Yingqian Li, Huashan Li. Evaluation of treatment methods for complete rectal prolapse: a real world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(06): 700-705.
[14]	Yongtong Wang, Heiying Jin, Chunxia Zhang, Xiaorui Ye, Jun Wang, Yang Yang, Jianlei Liu, Xinyi Zhang. Efficacy of magnetic stimulation combined with biofeedback in treatment of pelvic floor dysfunction: a prospective nonrandomized controlled study [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(07): 621-625.
[15]	Yong Fan, Lifan Zhang, Meilin Yang. Efficacy of modified peroral endoscopic cardial costriction on gastroesophageal reflux disease [J]. Chinese Journal of Gastroesophageal Reflux Disease(Electronic Edition), 2023, 10(02): 65-68.

Please choose a citation manager

Content to export